Novo Nordisk (NOVO) Status update summary

Wegovy supply

• US contract manufacturer halted Wegovy pen syringe production and deliveries temporarily after Good Manufacturing Practices issues.

• US demand is expected to exceed supply in H1 2022; few new patients are expected to initiate treatment, with priority given to existing patients.

• US demand is currently expected to be met in H2 2022.

Financial outlook and timing

• Supply challenges do not affect the previously communicated 2021 financial outlook.

• 2022 financial outlook is scheduled for release with FY 2021 results on 2 February 2022.